These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 12195108)

  • 1. Central effects of mineralocorticoids on blood pressure: new answers, new questions.
    Funder JW
    J Hypertens; 2002 Sep; 20(9):1715-6. PubMed ID: 12195108
    [No Abstract]   [Full Text] [Related]  

  • 2. Differential central effects of mineralocorticoid and glucocorticoid agonists and antagonists on blood pressure.
    van den Berg DT; de Kloet ER; van Dijken HH; de Jong W
    Endocrinology; 1990 Jan; 126(1):118-24. PubMed ID: 2293978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mineralocorticoid receptor ligands: biochemical, pharmacological, and clinical aspects.
    Sutanto W; de Kloet ER
    Med Res Rev; 1991 Nov; 11(6):617-39. PubMed ID: 1662327
    [No Abstract]   [Full Text] [Related]  

  • 4. Brain mineralocorticoid receptor control of blood pressure and kidney function in normotensive rats.
    Rahmouni K; Barthelmebs M; Grima M; Imbs JL; Wybren De Jong
    Hypertension; 1999 May; 33(5):1201-6. PubMed ID: 10334812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of brain mineralocorticoid receptor blockade on blood pressure and renal functions in DOCA-salt hypertension.
    Rahmouni K; Sibug RM; De Kloet ER; Barthelmebs M; Grima M; Imbs JL; De Jong W
    Eur J Pharmacol; 2002 Feb; 436(3):207-16. PubMed ID: 11858800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Brain mineralocorticoid receptor and blood pressure control in the conscious normotensive rat].
    Rahmouni K; Barthelmebs M; Imbs JL; De Jong W
    Arch Mal Coeur Vaiss; 1998 Aug; 91(8):1009-12. PubMed ID: 9749155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis.
    Sica DA
    Heart Fail Rev; 2005 Jan; 10(1):23-9. PubMed ID: 15947888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mineralocorticoid modulation of central control of blood pressure.
    Gómez Sánchez EP
    Steroids; 1995 Jan; 60(1):69-72. PubMed ID: 7792819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The influence of aldosterone and aldosterone antagonists on the pressor effect of synthetic Angiotensin II in primary chronic adrenal cortex insufficiency (M. Addison)].
    Koczorek KR; Avenhaus H
    Klin Wochenschr; 1966 Jul; 44(14):848-50. PubMed ID: 4296815
    [No Abstract]   [Full Text] [Related]  

  • 10. Hypertension and the mineralocorticoid receptor in the brain.
    Gómez Sánchez EP
    Ann N Y Acad Sci; 1994 Nov; 746():415-7. PubMed ID: 7825903
    [No Abstract]   [Full Text] [Related]  

  • 11. Inhibition of tissue repair by spironolactone: role of mineralocorticoids in fibrous tissue formation.
    Slight SH; Chilakamarri VK; Nasr S; Dhalla AK; Ramires FJ; Sun Y; Ganjam VK; Weber KT
    Mol Cell Biochem; 1998 Dec; 189(1-2):47-54. PubMed ID: 9879653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative dose-effect studies with four C-17-spirosteroidal mineralocorticoid synthesis inhibitors.
    Weindel K; Lewicka S; Vecsei P
    J Steroid Biochem; 1989; 34(1-6):455-9. PubMed ID: 2626039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood pressure versus direct mineralocorticoid effects on kidney inflammation and fibrosis in DOCA-salt hypertension.
    Klanke B; Cordasic N; Hartner A; Schmieder RE; Veelken R; Hilgers KF
    Nephrol Dial Transplant; 2008 Nov; 23(11):3456-63. PubMed ID: 18515791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eplerenone in mild heart failure.
    Gus M; Fuchs FD
    N Engl J Med; 2011 Apr; 364(14):1370-1; author reply 1372. PubMed ID: 21470019
    [No Abstract]   [Full Text] [Related]  

  • 15. Central effects of mineralocorticoid antagonist RU-28318 on blood pressure of DOCA-salt hypertensive rats.
    Van den Berg DT; de Kloet ER; de Jong W
    Am J Physiol; 1994 Dec; 267(6 Pt 1):E927-33. PubMed ID: 7810636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence that high dose cortisol-induced Na+ retention in man is not mediated by the mineralocorticoid receptor.
    Whitworth JA; Kelly JJ
    J Endocrinol Invest; 1995; 18(7):586-91. PubMed ID: 9221279
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of mineralocorticoid activity on transtubular potassium gradient, urinary [K]/[Na] ratio, and fractional excretion of potassium.
    Chacko M; Fordtran JS; Emmett M
    Am J Kidney Dis; 1998 Jul; 32(1):47-51. PubMed ID: 9669423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular and renal effects of central administration of a mineralocorticoid receptor antagonist in conscious female rats.
    Rahmouni K; Barthelmebs M; Grima M; Imbs JL; De Jong W
    Eur J Pharmacol; 1999 Dec; 385(2-3):199-202. PubMed ID: 10607876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of captopril, spironolactone, and simvastatin on the cardiovascular system of non-diseased Wistar rats.
    Simko F; Pechanova O; Krajcirovicova K; Matuskova J; Pelouch V; Adamcova M; Paulis L
    Int J Cardiol; 2015; 190():128-30. PubMed ID: 25918064
    [No Abstract]   [Full Text] [Related]  

  • 20. False claims of blood pressure-independent protection by blockade of the renin angiotensin aldosterone system?
    Kurtz TW
    Hypertension; 2003 Feb; 41(2):193-6. PubMed ID: 12574079
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.